- Conditions
- Pre-diabetes
- Interventions
- Normal Diet, Low carb diet, CGM with no real time feedback, CGM with real time feedback), Education material
- Other · Device · Behavioral
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Livonia, Michigan
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 44
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Lactose Intolerance
- Interventions
- GIMate, H2 Check
- Diagnostic Test
- Lead sponsor
- Vivante Health
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Carbohydrate Intolerance
- Interventions
- Low-FODMAP diet group (LFD), Low Sugar diet group (LAS)
- Other
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 5 Years to 18 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Springfield, Oregon
- Conditions
- Pre-diabetic
- Interventions
- Sugar Pill, XOS 2.8
- Dietary Supplement
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 20 Years to 70 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Pediatric Obesity, Insulin Resistance, Impaired Glucose Tolerance, Cardiovascular Disease
- Interventions
- Acarbose
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 12 Years to 25 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Metabolic Syndrome, Non-Alcoholic Fatty Liver Disease, NAFLD, Pre-diabetes
- Interventions
- Diet Intervention
- Behavioral
- Lead sponsor
- University of Texas at Austin
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Pre Diabetic, Hyperglycaemia (Non Diabetic)
- Interventions
- Combines group sessions and CGM-based behavioral feedback
- Other
- Lead sponsor
- Sam Houston State University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 2
- States / cities
- Conroe, Texas
- Conditions
- Allergy, Fatigue, Hypoglycemia, Hyperglycemia, Indigestion
- Interventions
- NAET Testing Modalities
- Procedure
- Lead sponsor
- Nambudripad's Allergy Research Foundation
- Other
- Eligibility
- 22 Years to 70 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2006
- U.S. locations
- 1
- States / cities
- Buena Park, California
- Conditions
- Glucose Control, Prediabetes (Insulin Resistance, Impaired Glucose Tolerance), Precision Medicine, Nutrition
- Interventions
- Premeal almond ingestion
- Dietary Supplement
- Lead sponsor
- Pennington Biomedical Research Center
- Other
- Eligibility
- 25 Years to 50 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Baton Rouge, Louisiana
- Conditions
- Diabetes, Pre Diabetes
- Interventions
- Viome's Precision Nutrition Program (VPNP)
- Dietary Supplement
- Lead sponsor
- Viome
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Bothell, Washington
- Conditions
- Pre-diabetes
- Interventions
- Control, Xenin-25 without atropine, GIP without atropine, Placebo with atropine, Xenin-25 with atropine, GIP with atropine, GIP plus Xenin-25 without atropine, GIP plus Xenin-25 with atropine
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Spinal Muscular Atrophy, Fragile X Syndrome, Fragile X - Premutation, Duchenne Muscular Dystrophy, Hyperinsulinemic Hypoglycemia, Familial 1, Diabetes Mellitus, Adrenoleukodystrophy, Neonatal, Medium-chain Acyl-CoA Dehydrogenase Deficiency, Very Long Chain Acyl Coa Dehydrogenase Deficiency, Beta-ketothiolase Deficiency, Severe Combined Immunodeficiency Due to Adenosine Deaminase Deficiency, Primary Hyperoxaluria Type 1, Congenital Bile Acid Synthesis Defect Type 2, Pyridoxine-Dependent Epilepsy, Hereditary Fructose Intolerance, Hypophosphatasia, Hyperargininemia, Mucopolysaccharidosis Type 6, Argininosuccinic Aciduria, Citrullinemia, Type I, Wilson Disease, Maple Syrup Urine Disease, Type 1A, Maple Syrup Urine Disease, Type 1B, Biotinidase Deficiency, Neonatal Severe Primary Hyperparathyroidism, Intrinsic Factor Deficiency, Usher Syndrome Type 1D/F Digenic (Diagnosis), Cystic Fibrosis, Stickler Syndrome Type 2, Stickler Syndrome Type 1, Alport Syndrome, Autosomal Recessive, Alport Syndrome, X-Linked, Carbamoyl Phosphate Synthetase I Deficiency Disease, Carnitine Palmitoyl Transferase 1A Deficiency, Carnitine Palmitoyltransferase II Deficiency, Cystinosis, Chronic Granulomatous Disease, Cerebrotendinous Xanthomatoses, Maple Syrup Urine Disease, Type 2, Severe Combined Immunodeficiency Due to DCLRE1C Deficiency, Thyroid Dyshormonogenesis 6, Thyroid Dyshormonogenesis 5, Supravalvar Aortic Stenosis, Factor X Deficiency, Hemophilia A, Hemophilia B, Tyrosinemia, Type I, Fructose 1,6 Bisphosphatase Deficiency, Glycogen Storage Disease Type I, G6PD Deficiency, Glycogen Storage Disease II, Galactokinase Deficiency, Mucopolysaccharidosis Type IV A, Galactosemias, Guanidinoacetate Methyltransferase Deficiency, Agat Deficiency, Glutaryl-CoA Dehydrogenase Deficiency, Gtp Cyclohydrolase I Deficiency, Hyperinsulinism-Hyperammonemia Syndrome, Primary Hyperoxaluria Type 2, 3-Hydroxyacyl-CoA Dehydrogenase Deficiency, Long-chain 3-hydroxyacyl-CoA Dehydrogenase Deficiency, Mitochondrial Trifunctional Protein Deficiency, Sickle Cell Disease, Beta-Thalassemia, Holocarboxylase Synthetase Deficiency, 3-Hydroxy-3-Methylglutaric Aciduria, Primary Hyperoxaluria Type 3, Hermansky-Pudlak Syndrome 1, Hermansky-Pudlak Syndrome 4, Apparent Mineralocorticoid Excess, HSDB, CBAS1, Mucopolysaccharidosis Type 2, Mucopolysaccharidosis Type 1, Severe Combined Immunodeficiency, X Linked, Severe Combined Immunodeficiency Due to IL-7Ralpha Deficiency, Diabetes Mellitus, Permanent Neonatal, Isovaleric Acidemia, Severe Combined Immunodeficiency T-Cell Negative B-Cell Positive Due to Janus Kinase-3 Deficiency (Disorder), Jervell and Lange-Nielsen Syndrome 2, Hyperinsulinemic Hypoglycemia, Familial, 2, Diabetes Mellitus, Permanent Neonatal, With Neurologic Features, Jervell and Lange-Nielsen Syndrome 1, Lysosomal Acid Lipase Deficiency, CblF, 3-Methylcrotonyl CoA Carboxylase 1 Deficiency, 3-Methylcrotonyl CoA Carboxylase 2 Deficiency, Waardenburg Syndrome Type 2A, Methylmalonic Aciduria cblA Type, Methylmalonic Aciduria cblB Type, Methylmalonic Aciduria and Homocystinuria Type cblC, MAHCD, Methylmalonic Aciduria Due to Methylmalonyl-CoA Mutase Deficiency, Congenital Disorder of Glycosylation Type 1B, Mthfr Deficiency, Methylcobalamin Deficiency Type Cbl G (Disorder), Methylcobalamin Deficiency Type cblE, Usher Syndrome, Type 1B, N-acetylglutamate Synthase Deficiency, Ornithine Transcarbamylase Deficiency, Phenylketonurias, Waardenburg Syndrome Type 1, Congenital Hypothyroidism, Propionic Acidemia, Usher Syndrome, Type 1F, Pancreatic Agenesis 1, Hereditary Hypophosphatemic Rickets, Glycogen Storage Disease IXB, Glycogen Storage Disease IXC, MOWS, Epilepsy, Early-Onset, Vitamin B6-Dependent, Pyridoxal Phosphate-Responsive Seizures, Pituitary Hormone Deficiency, Combined, 1, Ptsd, Dihydropteridine Reductase Deficiency, Severe Combined Immunodeficiency Due to RAG1 Deficiency, Severe Combined Immunodeficiency Due to RAG2 Deficiency, Retinoblastoma, Multiple Endocrine Neoplasia Type 2B, Pseudohypoaldosteronism, Type I, Liddle Syndrome, Biotin-Responsive Basal Ganglia Disease, SCD, DIAR1, GSD1C, Acrodermatitis Enteropathica, Thyroid Dyshormonogenesis 1, Riboflavin Transporter Deficiency, Waardenburg Syndrome, Type 2E, SRD, Congenital Lipoid Adrenal Hyperplasia Due to STAR Deficiency, Barth Syndrome, Adrenocorticotropic Hormone Deficiency, Transcobalamin II Deficiency, Thyroid Dyshormonogenesis 3, Segawa Syndrome, Autosomal Recessive, Autosomal Recessive Nonsyndromic Hearing Loss, Thyroid Dyshormonogenesis 2A, Congenital Isolated Thyroid Stimulating Hormone Deficiency, Hypothyroidism Due to TSH Receptor Mutations, Usher Syndrome Type 1C, Usher Syndrome Type 1G (Diagnosis), Von Willebrand Disease, Type 3, Combined Immunodeficiency Due to ZAP70 Deficiency, Adenine Phosphoribosyltransferase Deficiency, Metachromatic Leukodystrophy, Canavan Disease, Menkes Disease, Carbonic Anhydrase VA Deficiency, Developmental and Epileptic Encephalopathy 2, 17 Alpha-Hydroxylase Deficiency, Smith-Lemli-Opitz Syndrome, Krabbe Disease, Glutathione Synthetase Deficiency, Mucopolysaccharidosis Type 7, Rett Syndrome, Molybdenum Cofactor Deficiency, Type A, Niemann-Pick Disease, Type C1, Niemann-Pick Disease Type C2, Ornithine Aminotransferase Deficiency, 3-Phosphoglycerate Dehydrogenase Deficiency, Leber Congenital Amaurosis 2, Dravet Syndrome, Mucopolysaccharidosis Type 3 A, Ornithine Translocase Deficiency, Carnitine-acylcarnitine Translocase Deficiency, Glucose Transporter Type 1 Deficiency Syndrome, Creatine Transporter Deficiency, Niemann-Pick Disease Type A, Pitt Hopkins Syndrome, Tuberous Sclerosis 1, Tuberous Sclerosis 2, Ataxia With Isolated Vitamin E Deficiency, Angelman Syndrome, Prader-Willi Syndrome, Homocystinuria, Permanent Neonatal Diabetes Mellitus, Transient Neonatal Diabetes Mellitus, Factor VII Deficiency, Glycogen Storage Disease Type IXA1, Glycogen Storage Disease, Type IXA2, Glycogen Storage Disease IC, Glycogen Storage Disease Type IB, Central Hypoventilation Syndrome With or Without Hirschsprung Disease
- Interventions
- Confirmatory Testing
- Diagnostic Test
- Lead sponsor
- RTI International
- Other
- Eligibility
- 1 Day to 31 Days
- Enrollment
- 30,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2026
- U.S. locations
- 1
- States / cities
- Research Triangle Park, North Carolina
- Conditions
- Lactose Intolerance
- Interventions
- RP-G28
- Drug
- Lead sponsor
- Ritter Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Lactose Intolerance
- Interventions
- Not listed
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Lactose Intolerance
- Interventions
- Milk containing A1 and A2 beta-casein, Milk containing only A2 beta-casein
- Other
- Lead sponsor
- Purdue University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- West Lafayette, Indiana
- Conditions
- Lactose Intolerance
- Interventions
- Raw Milk, Pasteurized Milk, Non-dairy milk
- Behavioral
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Lactose Intolerance
- Interventions
- RP-G28 or placebo
- Drug
- Lead sponsor
- Ritter Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 2
- States / cities
- Honolulu, Hawaii • Dallas, Texas
- Conditions
- Prediabetic State
- Interventions
- BCAA High Protein supplement, BCAA Low Protein supplement
- Dietary Supplement
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 20 Years to 50 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Lactose Intolerance
- Interventions
- Bifidobacterium adolescentis IVS-1 capsule, Placebo cellulose capsule
- Dietary Supplement · Other
- Lead sponsor
- Purdue University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- West Lafayette, Indiana
- Conditions
- Diabetes Prevention
- Interventions
- DPP
- Behavioral
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2009
- U.S. locations
- 2
- States / cities
- Rochester, New York
- Conditions
- Lactose Intolerance
- Interventions
- RP-G28, Placebo
- Drug · Other
- Lead sponsor
- Ritter Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 377 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Princeton, New Jersey
- Conditions
- Fructose Intolerance
- Interventions
- Placedo, Alanine
- Dietary Supplement
- Lead sponsor
- Augusta University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 1
- States / cities
- Augusta, Georgia
- Conditions
- Diabetes, Obesity, Pre-Diabetes, Metabolic Syndrome
- Interventions
- Not listed
- Lead sponsor
- National Institute on Aging (NIA)
- NIH
- Eligibility
- 12 Years to 50 Years
- Enrollment
- 225 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2015
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Obesity, Glucose Intolerance, Diabetes, Acanthosis Nigricans
- Interventions
- Not listed
- Lead sponsor
- National Center for Research Resources (NCRR)
- NIH
- Eligibility
- 8 Years to 18 Years
- Healthy volunteers
- Accepts healthy volunteers
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut